A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)

Clinical trial NCT03987295 · COMPLETED

Trial details

NCT number: NCT03987295
Sponsor: Alector Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Frontotemporal Dementia

Start date: 2019-09-27
Primary completion: 2024-06-05
Enrollment: 33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.